An observational study in Heart Failure, sponsored by IRCCS San Raffaele Roma. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by IRCCS San Raffaele Roma · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 449 studies in Heart Failure with a site in Italy — 110 open to participants now, 130 under way, 18 of them phase 3. Heart Failure · Italy.
Among the 449 studies in Heart Failure with a site in Italy, this one is the 67th largest by planned enrollment of the 152 observational ones that give a count, is one of 34 that started in 2024, is one of 155 observational ones, reaches primary completion later than 63 of the 129 other live ones, and was the 403rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →110 of the 449 studies in Heart Failure with a site in Italy are open now. Recruiting first, the newest first:
Niguarda Hospital · Sites in Italy
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 29 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Bayer · Sites in Italy, United States, Argentina and 20 more countries
Ages up to 18
Biotronik SE & Co. KG · Sites in Italy, Australia, Austria and 10 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
449 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 48 · Phase 3 85 · Phase 4 36
First in 1983; this study’s year is marked. 34 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 200 across the 292 interventional studies, 353 across the 152 observational. Of the 252 that completed or were terminated, 91 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
205 of 449 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele Roma is the lead sponsor of 71 studies on the registry; 25 are open to participants now.
IRCCS San Raffaele Roma has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
36 of the studies in Heart Failure with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT03775161Vectorious Medical Technologies Ltd.V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure | 2026-12 |
| NCT03994874Iperboreal Pharma SrlPeritoneal Ultrafiltration in Cardio Renal Syndrome. | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 449 studies in Heart Failure with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim of the proposal is to create an interactive AI-based multicentre prospective database to provide information on how to improve the QoC for pts with HF.This will provide detailed information on pts characteristics,treatment practices, adherence to prescribed guideline-based optimal drug therapy,and outcomes.The database stems from a registry started two years ago,conceived to provide a contemporary snapshot on the adherence to the latest European GGLL for the therapeutic management of pts with HF.The database will be integrated with a specifically designed algorithm that provides an accurate feedback on whether patients are properly treated according to the ESC most recent recommendations.The expected outcomes are:-define non-adherence level to GGLL-based recommendations for treatment of HF;-provide information on initiation, adherence and persistence over time of the recommended treatment;-reduce medical inertia;produce practical implications to reduce morbidity and mortality
Heart Failure (HF) is a worldwide leading cause of death and continues to increase, with important implications for healthcare providers. International guidelines (GGLL) for patients with HF recommend a combination of drugs to reduce the risk of events and improve patient¿s symptoms. However, the current impact of guideline-directed medical therapies on mortality and morbidity remains limited because population of HF patients is very different from that enrolled in clinical trials, which is much older and therefore suffers multiple comorbidities, with the need of higher precision therapy based on their phenotype. Therefore, medical inertia is another lack of adherence factor and bad outcomes for HF patients. The aim of the proposal is to create an interactive multicentre prospective database initiated to provide information on how to improve the quality of care for patients (pts) with HF. The database will provide detailed information on pts characteristics, treatment practices, adherence to prescribed guideline, based optimal drug therapy and outcomes. Populations and Methods: The database stems from a registry that started two years ago. This registry was conceived to provide a contemporary snapshot adherence to the latest European guidelines for HF. The database will be integrated with a specifically designed artificial intelligence-based algorithm that provides an accurate feedback on whether patients are properly treated according to the European Society of Cardiology (ESC) most recent and updated recommendations for the treatment of patients with HF, suggesting the right therapy and target dosage based on patients¿ phenotype, clinical characteristic and comorbidities. According to HF drug major trials results, the algorithm will calculate the saved hospitalizations, urgent visits for decompensated HF and death for HF. Using an algorithm, created by inquiring about a recently started HF registry, this project will be able to produce practical implications to reduce morbidity and mortality in pts with HF, thanks to the increase of pts adherence to optimal treatments and physician¿s compliance to GGLL.
Patients with heart Failure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
create a registry that provides an updated assessment of the pattern of use of treatments recommended by guidelines in order to collect new evidence on compliance with them. Be they European or Italian for the treatment of patients with increased cardiov
Time frame: from enrollment to the end of observation al 24 months
Started Nov 2024 (actual). Primary completion is estimated for Feb 2027, 26 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 26 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2025 → Feb 2027 and completion Aug 2025 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS San Raffaele Roma